Now, let's get back to our question. Could this smaller biotech follow in the footsteps of its bigger partner? Their paths are a bit different: Vertex focused on CF for a number of years, building a billion-dollar business that's allowed it to fund programs in other areas. CRISPR Therapeutics has been applying its technology across treatment areas in preclinical and clinical studies for some time. CRISPR Therapeutics could start reporting product revenue soon. Vertex remains an excellent investment, but inv ...